Core Insights - Elevation Oncology is advancing EO-1022, a differentiated HER3 antibody-drug conjugate (ADC) aimed at addressing unmet medical needs in various solid tumors, with an IND application expected in 2026 [1][4][6] Group 1: Product Development - EO-1022 is designed with features such as glycan site-specific conjugation and MMAE payloads, which may enhance efficacy and safety for patients with solid tumors [2] - The ADC consists of seribantumab, a fully human IgG2 anti-HER3 monoclonal antibody, conjugated to the MMAE payload with a drug-to-antibody ratio (DAR) of 4 [2][4] - Preclinical data indicate that EO-1022 shows enhanced stability and anti-tumor activity compared to benchmark HER3 ADCs in both in vitro and in vivo models [2][5] Group 2: Clinical Potential - EO-1022 demonstrates potent in vitro cytotoxicity that is dependent on HER3 expression levels and elicits anti-tumor activity across various HER3 expression levels in vivo [5] - The ADC is being developed for HER3-expressing solid tumors, including breast cancer and non-small cell lung cancer [4][6] Group 3: Company Overview - Elevation Oncology focuses on the discovery and development of selective cancer therapies to meet significant unmet medical needs in oncology [5][6] - The company leverages its expertise in ADC technology to advance EO-1022, which is currently in preclinical development [5][6]
Elevation Oncology Presents Preclinical Proof-of-Concept Data for EO-1022 at the American Association for Cancer Research (AACR) Annual Meeting 2025